Oncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Oncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment ; volume:7 ; number:1 ; day:12 ; month:7 ; year:2017 ; pages:1-13 ; date:12.2017
Scientific reports ; 7, Heft 1 (12.7.2017), 1-13, 12.2017
- Creator
-
Chen, Aiping
- Contributor
-
Zhang, Yonghui
Meng, Gang
Jiang, Dengxu
Zhang, Hailin
Zheng, Meihong
Xia, Mao
Jiang, Aiqin
Wu, Junhua
Beltinger, Christian
Wei, Jiwu
SpringerLink (Online service)
- DOI
-
10.1038/s41598-017-05500-z
- URN
-
urn:nbn:de:101:1-2018080901360580474484
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chen, Aiping
- Zhang, Yonghui
- Meng, Gang
- Jiang, Dengxu
- Zhang, Hailin
- Zheng, Meihong
- Xia, Mao
- Jiang, Aiqin
- Wu, Junhua
- Beltinger, Christian
- Wei, Jiwu
- SpringerLink (Online service)
Other Objects (12)
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Advances in antitumour therapy with oncolytic herpes simplex virus combinations
Engineering targeted and cytokine-armed oncolytic measles viruses
BiTE-armed oncolytic measles viruses for cancer immunovirotherapy
BiTE-armed oncolytic measles viruses for cancer immunovirotherapy
Key parameters of measles virus production for oncolytic virotherapy
Analysis of primary resistance phenomena to oncolytic measles vaccine virus
MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus
Versatility of DARPin-targeted oncolytic measles viruses : safety, efficacy, and specificity
Armed oncolytic measles vaccine virus for the treatment of hepatocellular carcinoma
Oncolytic measles virus MV-NIS controls relapsed pediatric ALL patient-derived xenografts
MicroRNA-sensitive oncolytic measles virus vectors for chemovirotherapy of pancreatic cancer
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Advances in antitumour therapy with oncolytic herpes simplex virus combinations
Engineering targeted and cytokine-armed oncolytic measles viruses
BiTE-armed oncolytic measles viruses for cancer immunovirotherapy
BiTE-armed oncolytic measles viruses for cancer immunovirotherapy
Key parameters of measles virus production for oncolytic virotherapy
Analysis of primary resistance phenomena to oncolytic measles vaccine virus
MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus
Versatility of DARPin-targeted oncolytic measles viruses : safety, efficacy, and specificity
Armed oncolytic measles vaccine virus for the treatment of hepatocellular carcinoma
Oncolytic measles virus MV-NIS controls relapsed pediatric ALL patient-derived xenografts
MicroRNA-sensitive oncolytic measles virus vectors for chemovirotherapy of pancreatic cancer
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Advances in antitumour therapy with oncolytic herpes simplex virus combinations
Engineering targeted and cytokine-armed oncolytic measles viruses
BiTE-armed oncolytic measles viruses for cancer immunovirotherapy
BiTE-armed oncolytic measles viruses for cancer immunovirotherapy
Key parameters of measles virus production for oncolytic virotherapy
Analysis of primary resistance phenomena to oncolytic measles vaccine virus
MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus
Versatility of DARPin-targeted oncolytic measles viruses : safety, efficacy, and specificity
Armed oncolytic measles vaccine virus for the treatment of hepatocellular carcinoma
Oncolytic measles virus MV-NIS controls relapsed pediatric ALL patient-derived xenografts